ITM Radiopharma’s Phase III trial of its targeted radiotherapeutic for patients with Grade 1 or 2 gastroenteropancreatic ...

The company now has RayzeBio's pipeline, including its late-stage targeted radiopharma therapy, RYZ101, for gastroenteropancreatic neuroendocrine tumors. It is also in a phase one trial for small ...

Cabometyx is approved for treating well-differentiated pancreatic and extra-pancreatic neuroendocrine tumors in patients 12 years and older. The phase 3 CABINET trial showed improved progression-free ...

The drug is being developed for gastroenteropancreatic neuroendocrine tumor, pancreatic net, neuroendocrine tumors, extensive stage small cell lung cancer (ES-SCLC), and other tumors. Currently ...

Targeted radionuclide therapy, another type of systemic radiation therapy, can treat advanced prostate cancer or gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Sometimes your doctor can ...

well-differentiated pancreatic neuroendocrine tumors (pNET) and extrapancreatic NET (epNET). Specifically, the approval is for those with unresectable, locally advanced, or metastatic pNET and ...

Currently, her areas of focus include the development of novel theranostic agents for pancreatic cancers and understanding the role of Notch signaling in gastroenteropancreatic neuroendocrine tumors.

NSCLC = non-small cell lung cancer; CUP = carcinoma of unknown primary; CCC = cholangiocarcinoma; GEP-NET= Gastroenteropancreatic neuroendocrine tumor. Image created with contributions from ...